1285 related articles for article (PubMed ID: 8873049)
1. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine.
Knight BC; Souberbielle BE; Rizzardi GP; Ball SE; Dalgleish AG
Melanoma Res; 1996 Aug; 6(4):299-306. PubMed ID: 8873049
[TBL] [Abstract][Full Text] [Related]
2. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model.
Labarthe MC; Halanek N; Birchall L; Russell N; Desel C; Todryk S; Peters MJ; Lucas A; Falkenberg FW; Dalgleish AG; Whelan M; Ward SJ
Cancer Immunol Immunother; 2006 Mar; 55(3):277-88. PubMed ID: 16158275
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.
Todryk SM; Birchall LJ; Erlich R; Halanek N; Orleans-Lindsay JK; Dalgleish AG
Immunology; 2001 Feb; 102(2):190-8. PubMed ID: 11260324
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.
Kircheis R; Küpcü Z; Wallner G; Rössler V; Schweighoffer T; Wagner E
Cancer Gene Ther; 2000 Jun; 7(6):870-8. PubMed ID: 10880017
[TBL] [Abstract][Full Text] [Related]
6. Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model.
Mac Keon S; Bentivegna S; Levy EM; Marks MS; Mantegazza AR; Wainstok R; Mordoh J
Vaccine; 2019 Aug; 37(35):4947-4955. PubMed ID: 31307876
[TBL] [Abstract][Full Text] [Related]
7. Optimization of intracerebral tumour protection by active-specific immunization against murine melanoma B16/G3.12.
Staib L; Harel W; Mitchell MS
Melanoma Res; 2001 Aug; 11(4):325-35. PubMed ID: 11479420
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model.
Souberbielle BE; Westby M; Ganz S; Kayaga J; Mendes R; Morrow WJ; Dalgleish AG
Gene Ther; 1998 Nov; 5(11):1447-54. PubMed ID: 9930297
[TBL] [Abstract][Full Text] [Related]
9. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Russell SJ; Collins MK; Cohen EP
Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
[TBL] [Abstract][Full Text] [Related]
10. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.
Kim TS; Russell SJ; Collins MK; Cohen EP
Int J Cancer; 1993 Nov; 55(5):865-72. PubMed ID: 8244584
[TBL] [Abstract][Full Text] [Related]
11. An autologous oral DNA vaccine protects against murine melanoma.
Xiang R; Lode HN; Chao TH; Ruehlmann JM; Dolman CS; Rodriguez F; Whitton JL; Overwijk WW; Restifo NP; Reisfeld RA
Proc Natl Acad Sci U S A; 2000 May; 97(10):5492-7. PubMed ID: 10779556
[TBL] [Abstract][Full Text] [Related]
12. Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity.
Todryk SM; Eaton J; Birchall L; Greenhalgh R; Soars D; Dalgleish AG; Melcher AA; Pandha HS
Cancer Immunol Immunother; 2004 Apr; 53(4):323-30. PubMed ID: 14648067
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
[TBL] [Abstract][Full Text] [Related]
14. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
15. A novel murine model of allogeneic vaccination against prostate cancer.
Labarthe MC; Theocharous P; Russell N; Todryk S; Bangma C; Thraves P; Dalgleish AG; Whelan MA
Cancer Immunol Immunother; 2008 Apr; 57(4):453-65. PubMed ID: 17805533
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.
Kurzawa H; Wysocka M; Aruga E; Chang AE; Trinchieri G; Lee WM
Cancer Res; 1998 Feb; 58(3):491-9. PubMed ID: 9458095
[TBL] [Abstract][Full Text] [Related]
17. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine.
Souberbielle BE; Knight BC; Morrow WJ; Darling D; Fraziano M; Marriott JB; Cookson S; Farzaneh F; Dalgleish AG
Gene Ther; 1996 Oct; 3(10):853-8. PubMed ID: 8908498
[TBL] [Abstract][Full Text] [Related]
18. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
19. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
20. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
